By Stephen Nakrosis
Avita Medical said the U.S. Food and Drug Administration has approved the company's premarket approval supplement for Recell Go mini, a system to treat smaller wounds.
The Recell Go mini is a line extension of the Recall Go system, and is designed as a treatment for wounds up to 480 square centimeters. The standard Recall Go system treats an area of 1,920 square centimeters, the company said.
Avita said the Recell Go mini can serve as an entry point for clinicians who are unfamiliar with the system, and will allow broader accessibility and use in trauma and burn centers.
Roll out of the Recell Go mini will begin during the first quarter of 2025, the company said.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
December 23, 2024 16:26 ET (21:26 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。